Enzo Biochem Inc

Enzo Biochem — Investor Presentation (January 2021)

23 slides from Enzo Biochem's investor presentation, Jan 6, 2021

  1. Slide 1: A Year of Challenges, Opportunities & Achievements – Investor Presentation

    7Enzo Scientists Enabling Healthcare™ < A Year of Challenges; @pportunitiéS & Achievements ® Investor Presentation

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Except for historical information, the matters discussed in this presentation may be considered "forward- looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Su

  3. Slide 3: Promises Delivered — Enzo Biochem

    Promises Delivered — Enzo Biochem ° The company recently announced its best financial results in Enzo’s history and the fulfilling of its three core objectives: 1. Building infrastructure for strategic diagnostic products and services growth 2. Implementing efficiency measures with a return to opera

  4. Slide 4: 2020: A Year Of Innovation & Important Achievements For Enzo

    Enzo Scientists Enabling Healthcare™ 2020: A Year Of Innovation & Important Achievements For Enzo

  5. Slide 5: Company Snapshot

    Company Snapshot +40% YoY Revenue Growth > FY21E ~ $115M . . . . - , Achieved Profitability Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform 0. , ; techn

  6. Slide 6: Products & Services to Meet Every Healthcare Need

    Products & Services to Meet Every Healthcare Need Molecular Diagnostics e————————__ Physicians / Urgent Care \ e————___ Hospitals / Health Networks Immunoassays ——————— Ei a Genetics & Genomics e——————___ o———— _ Concierge Services “A e—_—_____ Direct to Consumer «——————— Contract Research Organizat

  7. Slide 7: Notable 2020 Achievements

    Notable 2020 Achievements In the face of unprecedented challenges, Enzo’s strategic forethought and decisive responsiveness led to significant achievements- in terms of both financial performance and strategic accomplishments. Enzo Biochem’s Clinical Labs Subsidiary Launches Drive-Through Facility t

  8. Slide 8: Strategic / Operational Accomplishments

    Strategic / Operational Accomplishments ¢ Our foresight and strategic investment in the GENFLEX™ platform drove our operational success in 2020 ¢ Stabilized and grew business while ensuring safety, job security, and morale of employees during the pandemic — PPP: $7 million loan to help address early

  9. Slide 9: Strategic / Operational Accomplishments (continued)

    Strategic / Operational Accomplishments (continued) Continued focus on core growth initiatives delivered strong results: e FDA EVA approval for diagnostic products and services - GENFLEX™ platforms now running in our lab Continued expansion of prolific patent portfolio - 42 new patents granted & 23

  10. Slide 10: Transforming Molecular Diagnostics to a Modern Platform

    Enzo Scientists Enabling Healthcare™ Transforming Molecular Diagnostics to a Modern Platform

  11. Slide 11: Enzo's Decentralized Approach

    Enzo’s Decentralized Approach Investing in the future of fully integrated end-to-end diagnostic solutions Witnessing the external industry challenges firsthand such as: Affordable Care Act (ACA) Protecting Access to Medicare Act \ (PAMA) ) Centralized Laboratory Testing Y (Commoditization) Legacy Eq

  12. Slide 12: ENZO's Proprietary GENFLEX Platform

    ENZO’s Proprietary GENFLEX™ Platform Developed to address systemic issues across the Molecular Diagnostics Industry GENFLEX™ FDA Approval (EVA) July 2020 for it’s COVID-19 test, which positioned Enzo as a leader in molecular diagnostics and services. Capabilities are being extended to Women’s Health

  13. Slide 13: Accelerated Demand for Molecular Diagnostics

    Accelerated Demand for Molecular Diagnostics Renewed Appreciation for Molecular Testing Awareness of the risk of pandemic has reinforces the critical role that diagnostic testing plays Unified in global health. Need Stakeholders including Patients, Providers, Government Agents and Payers understand

  14. Slide 14: Commercial Approach To Expanding Test Access

    Commercial Approach To Expanding Test Access Serve Multiple Constituents Local Govt. Work) Municipal Business Offices Urgent Care | Pharmacies Schools/ “ Houses of Education ' , Worshi Long-term $ a uD Care Facilities Online > A Drive up Primary Test Access hoeeeme Clinics 14 Secondary Test Access E

  15. Slide 15: Focus Areas — Progress on Novel Diagnostic Platforms

    Focus Areas — Progress on Novel Diagnostic Platforms COVID-19 Pooling, ELISA Micro-plate Flu AB, nee lial & COVID-19 IgG [> COVID-19 Vaccine Immunity Developing New Platform Analyte-specific Working with Partners on reagents Full Workflow Potential Partners ‘5 Enzo

  16. Slide 16: Enzo's Financial Performance

    Enzo Scientists Enabling Healthcare™ Enzo’s Financial Performance

  17. Slide 17: Financial Snapshot

    Financial Snapshot Quarterly Revenue (USD M) Annual Revenue (USD M) 120 220 320 420 att & Initial COVID effect in Q3 (Feb-Apr) Cash Position (as of 10/31/20) FY 19 FY 20 FY 216 (LQA) | | | $0.0 $10.0 $20.0 $30.0 $40.0 $50.0 $60.0 ” @Enzo

  18. Slide 18: Enzo Services Gross Margin

    Enzo Services Gross Margin 50.0% 45.0% 40.0% 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% 5.0% 0.0% aig 23.3% 219 8.1% Q3'19 6.7% Q4ig9 13.8% Q1'20 14.1% Q2'20 18.1% Q3'20 12.9% Q4'20 37.8% Q1'21 38.8% v GM in Services division increased to 38.8% in Q1 vs. 14.1% in previous year’s quarter v Rapid increase du

  19. Slide 19: Quarterly EBITDA and EPS

    19 Quarterly EBITDA and EPS Qi Qi YoY 2021 2020 Change EBITDA $1.0mm ($7.1mm) $8.1mm Adj. EBITDA $1.0mm ($5.7mm) $6.7mm EPS $0.01 ($0.16) $0.17 Adj. EPS $0.01 ($0.13) $0.14 @Enzo

  20. Slide 20: Well Positioned for New Levels of Success in 2021

    20 Well Positioned for New Levels of Success in 2021 v Our expanded operations and enhanced capabilities position Enzo as an integrated end-to- end diagnostics company able to deliver the full range of innovative products and services the market demands ¥_ Facility Expansion: With favorable tax ince

  21. Slide 21: Investment Highlights

    Investment Highlights Best In Class MDx Platform Supported By Fully-integrated Biotech, Life Sciences And Lab Services Business Capitalizing on industry tailwinds amid accelerated global demand for unique diagnostic platform technologies —> COVID-19 Testing & Platform-Flexible Solutions . F A A . 5

  22. Slide 22: Primed for Continued Success

    22 Primed for Continued Success y¥ Unique vertical integration enables innovation and disruption within the healthcare market < Capitalizing on industry tailwinds amid tremendous demand for molecular diagnostics v Actively addressing COVID-19 from multiple angles g “+ Virus Detection > Ampiprobe® SA

  23. Slide 23: Thank You

    101010%% Enzo Scientists Enabling Healthcare™ Thank You www.enzo.com IR@enzo.com

Enzo Biochem — Investor Presentation (January 2021) on 6ix